Register

Registration

Disclaimer
Terms and Conditions
Questionnaires / Survey
Note : After Answered of Questionnaires / Survey Please Close it.
.

Wanbury Ltd . Small Cap

BSE: 524212 | NSE: WANBURY
Pharmaceuticals
Live
20/04/2021 4:00:00 PM
97.95 4.05   (4.31%)
BSE: price shown with 5 mins delayed.
Prev. Close 93.90
Open Price 94.00
Volume Traded 17460.00

Fundamentals

Mar'10 Mar'11 Mar'12 Mar'13 Mar'15 Mar'16 Mar'17 Mar'18 Mar'19 Mar'20
Ajusted EPS(Rs.) 5.56 0 0 0 0 0 3.21 3.21 0 26.71
Net Sales (Rs. Cr.) 472.59 387.42 386.25 459.11 661.86 661.86 249.92 249.92 423.26 433.8
Adjusted Net Profit 8.37 -83.47 -46.16 -87.01 -38.61 -38.61 3.22 3.22 -6.11 62
Book Value/ Share(Rs.) 75.92 17.97 -2.96 -53.4 -108.9 -108.9 -109.34 -109.34 -112.87 -66.01
Cash Flow -15.07 -1.95 1.99 2.75 -8.71 5.29 -8.71 5.29 -4.65 3.40
Debt to Cash Flow from Operations 11.28 3.04 50.02 4.74 5.59 9.48 5.59 9.48 8.41 6.91
RONW 6.96 0.00 0.00 0.00 0.00 0.00 -9.51 -9.51 0.00 -117.17
ROCE % 8.91 0.00 0.00 0.00 0.00 0.00 13.29 13.29 0.00 33.42
Net Operating Profit Margin % 5.58 -19.07 -7.46 -13.80 -1.83 -1.83 3.64 3.64 0.68 16.39
Net Profit Margin % 1.77 -21.34 -11.80 -18.66 -5.72 -5.72 1.26 1.26 -1.41 13.98
Debt / Equity 3.90 5.15 11.70 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield % 1.32 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Mar'10 Mar'11 Mar'12 Mar'13 Mar'15 Mar'16 Mar'17 Mar'18 Mar'19 Mar'20
Ajusted EPS(Rs.) 20.2 0 0 0 0 0 3.21 3.21 0 26.71
Net Sales (Rs. Cr.) 351.11 315.24 344.55 414.14 661.86 661.86 249.92 249.92 423.26 433.8
Adjusted Net Profit 29.89 -21.95 -23.41 -25.25 -27.86 -27.86 3.23 3.23 -6.00 62.01
Book Value/ Share(Rs.) 88.95 70.27 52.25 39.92 -96.1 -96.1 -96.48 -96.48 -99.34 -54.91
Cash Flow -14.75 0.54 2.57 3.24 -8.71 5.29 -8.71 5.29 -4.54 3.40
Debt to Cash Flow from Operations 55.82 10.51 -9.75 10.24 5.17 9.51 5.17 9.51 8.65 6.29
RONW 0.00 0.00 0.00 0.00 0.00 0.00 -11.89 -11.89 0.00 -157.53
ROCE % 14.31 4.23 2.05 0.00 0.00 0.00 12.81 12.81 0.00 32.77
Net Operating Profit Margin % 11.31 -4.11 -4.00 -2.50 -0.24 -0.24 3.65 3.65 0.70 16.39
Net Profit Margin % 8.43 -6.95 -6.70 -6.03 -4.13 -4.13 1.26 1.26 -1.38 13.98
Debt / Equity 2.66 2.65 3.57 5.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield % 1.32 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Year on Year Growth Rate (%)

Ajusted EPS Sales Adjusted Net Profit

Latest Financials

Standalone Consolidated
TTM EPS (Rs) 0 0
TTM Sales (Rs. Cr.) 339.14 339.14
BVPS (Rs.) -50.97 -61.20
Reserves (Rs. Cr.) -152.53 -178.11
P/BV -1.87 -1.56
PE NM NM
From the Market
52 Week High / Low (Rs) 114.7/16.45
All Time High / Low (Rs) 267/0.85
Volume Traded 17460
Market Cap (Rs. Cr.) 234.89
Equity (Rs. Cr.) 25.015117
Face Value (Rs) 10
Industry PE 0

Quarterly Results

Mar'2020 Jun'2020 Sep'2020 Dec'2020
Net Sales (Cr) 67.07 67.16 95.21 109.70
Adjusted EPS (Rs) -7.99 -4.46 0.64 2.36
Net Profit Margin % -29.77 -16.62 1.68 5.39
Mar'2020 Jun'2020 Sep'2020 Dec'2020
Net Sales (Cr) 67.07 67.16 95.21 109.70
Adjusted EPS (Rs) -7.99 -4.46 0.64 2.36
Net Profit Margin % -29.77 -16.62 1.68 5.39

Quarterly Growth Rate (%)

Ajusted EPS Sales Net Profit Margin

Peers Data

Name Current Price(Rs) Market Cap. (Rs. cr.) Net Profit(Rs. cr.) Sales Growth(%)
Gujarat Terce Laboratories Ltd 7.23 5.65 0.28 -48.69
Parnax Lab Ltd 19.2 16.24 0 -79.17
Medi Caps Ltd 39.25 46.64 -8.33 -100.00
Lyka Labs Ltd 29.45 80.48 -53.19 -10.42
Ambalal Sarabhai Enterprises Ltd 21.55 154.8 0 0.00
Wanbury Ltd 95.3 234.89 64.46 -25.96
Aurobindo Pharma Ltd 987.4 56572.37 1872.74 -11.37
Cipla Ltd 949.3 76339.81 2318.17 -39.44
Dr Reddys Laboratories Ltd 5153.95 82660.96 2937.7 -15.73
Divis Laboratories Ltd 3783.8 101014.78 1372.71 -4.34
Sun Pharmaceuticals Industries Ltd 645.05 153629.42 3211.14 -20.62

Technical

Sector

23387.09 280.75   (1.22%)

Index

47705.80 -243.62   (-0.51%)
9 Days Avg
Span A Span B 52 Week TenKan-Sen Kijun-Sen ChiKou-Sen
9 Days Avg

Score

Kindly subscribe to get access

Research Analytical

Kindly subscribe to get access

News

About Company

Wanbury Ltd is the fastest growing pharma company with a Compounded Annual Growth Rate(CAGR) of 68% over the last 6 years.The company has strong presence in domestic formulations,Active Pharmaceutical Ingredient(API) and Contract Research and manufacturing Services(CRAMS).The company also has its presence in Europe in formulations.Wanbury was incorporated as Pearl Distributors Pvt Ltd in 1990.It went public and was renamed as Pearl Organics Ltd in 1991.The company has established its first plant in the year 1992 in Tarapur for manufacturing APIs.In 1995,Pearl Organics acquired plant of Brij Chemicals Pvt Ltd at Patalganga.In 1996,the company has entered into a strategic alliance with Wyckoff Chemicals to manufacture its API in US.In 2007,Pharmaceutical Products India Ltd was amalgamated with the company pursuant to the BIFR order.In the same year, Doctor's Organics and Chemicals Ltd also came into the fold of Wanbury as this also merged with Wanbury.The company has entered into a strategic association with Bravo Healthcare Ltd and also incorporated Ningxia Wanbury Fine Chemicals Co Ltd to source raw materials from China.The company has opened its office in Zurich,Switzerland for its CRAMS business and incorporated Wanbury Global FZE in Middle East for carrying out its trading activities in the year 2008.